SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of PTC Therapeutics Inc. (PTCT)

Feb 23, 2016, 11:19 ET from Bronstein, Gewirtz & Grossman, LLC

NEW YORK, Feb. 23, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of PTC Therapeutics Inc. ("PTC" or "the Company") (NASDAQ: PTCT). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at or 212-697-6484.

This investigation concerns whether PTC and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act"). 

PTC Therapeutics is a pharmaceutical company focused on the development of small molecule, orally administered treatments for orphan diseases. 

PTC received a refuse letter to file from the U.S. Food and Drug Administration (FDA) for its new drug, Translarna. Translarna is a protein restoration therapy designed to treat a form of muscular dystrophy which mostly affects men.  One news report commented that Translarna's application was not up to standards, disqualifying it from a full review. PTC responded that it is examining what its next steps are.

Following this news, on February 23, 2016, PTC stock fell more than 40% to a low of just $16.85 per share on early pre-market trading.

If you are aware of any facts relating to this investigation, or purchased shares of PTC Therapeutics Inc., you can assist this investigation by visiting the firm's website:!ptct/t7zco.  You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 |


SOURCE Bronstein, Gewirtz & Grossman, LLC